| abstract |
[Problem] To provide a therapeutic agent for treating and/or improving retinopathy caused by glucose. [Solution] This therapeutic agent for retinopathy caused by glucose is characterized by having a sodium / glucose cotransporter 2 inhibitor (SGLT2 inhibitor) as the active component. This therapeutic agent is used at a normal dosage, or at a low dosage, less than or equal to the normal dose, at which no fall in blood sugar is observed. |